Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Eye Res ; 37(10): 907-13, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22642649

ABSTRACT

PURPOSE: To investigate neuroprotective effects of siRNA targeted to caspase-3 against ischemia and reperfusion (I/R) injury in rat eyes. METHODS: Retinal ischemia was induced in Wistar rats by increasing the intraocular pressure (IOP) to 110 mmHg for 120 min. To examine the effect of siRNA on rat caspase-3, siRNA was injected into the vitreous cavity 24 h prior to induction of retinal ischemia. Eyes were removed at 2, 7 or 14 days later, and then analyzed for the number of retinal ganglion cells (RGCs), the retinal thickness and the amount of apoptosis of the retinal neural cells (as demonstrated by the TUNEL assay). The amount of caspase-3 mRNA was analyzed by rt-PCR. Differences between groups were evaluated by an unpaired t test. RESULTS: The numbers of RGCs in the saline and non-silencing siRNA controls were reduced significantly at 2 and 7 days after the I/R injury. RGCs were significantly retained in eyes pretreated with siRNA targeted to caspase-3 as compared to the control eyes at 2 days after the I/R injury. Inner retinal thickness in the control eyes was significantly thinner as compared to the treated eyes at 2 and 7 days after the I/R injury. After siRNA treatment, the amount of caspase-3 mRNA was significantly lower when compared to the saline control group. CONCLUSIONS: The injection of siRNA targeted to caspase-3 into the vitreous cavity of rat eyes may block caspase-3, and may thus be able to prevent retinal cell death associated with ischemic injury. As inhibition of the apoptosis pathway may provide a neuroprotective effect, examination of new strategies for treating these disorders needs to be undertaken.


Subject(s)
Caspase 3/genetics , Genetic Therapy/methods , RNA, Small Interfering/pharmacology , Reperfusion Injury/therapy , Retinal Diseases/therapy , Animals , Disease Models, Animal , In Situ Nick-End Labeling , Injections, Intraocular , Male , Neuroprotective Agents/pharmacology , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Rats , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reperfusion Injury/enzymology , Reperfusion Injury/pathology , Retinal Diseases/enzymology , Retinal Diseases/pathology , Retinal Ganglion Cells/enzymology , Retinal Ganglion Cells/pathology , Vitreous Body
SELECTION OF CITATIONS
SEARCH DETAIL
...